| Year |
Citation |
Score |
| 2023 |
Generali D, Berardi R, Caruso M, Cazzaniga M, Garrone O, Minchella I, Paris I, Pinto C, De Placido S. Aromatase inhibitors: the journey from the state of the art to clinical open questions. Frontiers in Oncology. 13: 1249160. PMID 38188305 DOI: 10.3389/fonc.2023.1249160 |
0.531 |
|
| 2023 |
Schettini F, Giudici F, Generali D. Therapeutic resistance and optimal drug sequencing in HER2-positive metastatic breast cancer: unmet needs and future perspectives. Heliyon. 10: e23367. PMID 38163142 DOI: 10.1016/j.heliyon.2023.e23367 |
0.389 |
|
| 2023 |
Zattarin E, Mariani L, Menichetti A, Leporati R, Provenzano L, Ligorio F, Fucà G, Lobefaro R, Lalli L, Vingiani A, Nichetti F, Griguolo G, Sirico M, Bernocchi O, Marra A, ... ... Generali D, et al. Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors. Therapeutic Advances in Medical Oncology. 15: 17588359231204857. PMID 38130467 DOI: 10.1177/17588359231204857 |
0.499 |
|
| 2023 |
Dri A, Arpino G, Bianchini G, Curigliano G, Danesi R, De Laurentiis M, Del Mastro L, Fabi A, Generali D, Gennari A, Guarneri V, Santini D, Simoncini E, Zamagni C, Puglisi F. Breaking barriers in triple negative breast cancer (TNBC) - Unleashing the power of antibody-drug conjugates (ADCs). Cancer Treatment Reviews. 123: 102672. PMID 38118302 DOI: 10.1016/j.ctrv.2023.102672 |
0.406 |
|
| 2023 |
Cazzaniga ME, Ademuyiwa F, Petit T, Tio J, Generali D, Ciruelos EM, Califaretti N, Poirier B, Ardizzoia A, Hoenig A, Lex B, Mouret-Reynier MA, Giesecke D, Isambert N, Masetti R, et al. Low RNA disruption during neoadjuvant chemotherapy predicts pCR absence in patients with breast cancer. Jnci Cancer Spectrum. PMID 38113421 DOI: 10.1093/jncics/pkad107 |
0.743 |
|
| 2023 |
Favero D, Generali D, Schettini F. Editorial: Diagnostic, prognostic and predictive factors of response in the era of precision oncology in breast cancer. Frontiers in Oncology. 13: 1337315. PMID 38074662 DOI: 10.3389/fonc.2023.1337315 |
0.478 |
|
| 2023 |
Conte B, Boni L, Bisagni G, Durando A, Sanna G, Gori S, Garrone O, Tamberi S, De Placido S, Schettini F, Pazzola A, Ponzone R, Montemurro F, Lunardi G, Notaro R, ... ... Generali D, et al. SNPs of aromatase predict long-term survival and aromatase inhibitor toxicity in patients with early breast cancer: a biomarker analysis of the GIM4 and GIM5 trials. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 37888299 DOI: 10.1158/1078-0432.CCR-23-1568 |
0.442 |
|
| 2023 |
Dieci MV, Conte PP, Bisagni PG, Bartolini S, Frassoldati A, Generali D, Piacentini F, Griguolo G, Tagliafico E, Brasó Maristany F, Chic N, Paré L, Miglietta F, Vicini R, D'Amico R, et al. Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancer. Journal of the National Cancer Institute. PMID 37676829 DOI: 10.1093/jnci/djad179 |
0.47 |
|
| 2023 |
Ferro A, Generali D, Caffo O, Caldara A, De Lisi D, Dipasquale M, Lorenzi M, Monteverdi S, Fedele P, Ciribilli Y. Oral selective estrogen receptor degraders (SERDs): The new emperors in breast cancer clinical practice? Seminars in Oncology. 50: 90-101. PMID 37673696 DOI: 10.1053/j.seminoncol.2023.08.002 |
0.332 |
|
| 2023 |
Zambelli A, Cazzaniga M, La Verde N, Munzone E, Antonazzo IC, Mantovani LG, Di Cosimo S, Mancuso A, Generali D, Cortesi PA. A cost-consequence analysis of adding pertuzumab to the neoadjuvant combination therapy in HER2-positive high-risk early breast cancer in Italy. Breast (Edinburgh, Scotland). 71: 113-121. PMID 37573652 DOI: 10.1016/j.breast.2023.08.005 |
0.432 |
|
| 2023 |
Schettini F, De Bonis MV, Strina C, Milani M, Ziglioli N, Aguggini S, Ciliberto I, Azzini C, Barbieri G, Cervoni V, Cappelletti MR, Ferrero G, Ungari M, Locci M, Paris I, ... ... Generali D, et al. Computational reactive-diffusive modeling for stratification and prognosis determination of patients with breast cancer receiving Olaparib. Scientific Reports. 13: 11951. PMID 37488154 DOI: 10.1038/s41598-023-38760-z |
0.699 |
|
| 2023 |
Schettini F, Fontana A, Gattazzo F, Strina C, Milani M, Cappelletti MR, Cervoni V, Morelli L, Curigliano G, Iebba V, Generali D. Faecal microbiota composition is related to response to CDK4/6-inhibitors in metastatic breast cancer: A prospective cross-sectional exploratory study. European Journal of Cancer (Oxford, England : 1990). 191: 112948. PMID 37454444 DOI: 10.1016/j.ejca.2023.112948 |
0.792 |
|
| 2023 |
Munzone E, Regan MM, Cinieri S, Montagna E, Orlando L, Shi R, Campadelli E, Gianni L, Palleschi M, Petrelli F, Bengala C, Generali D, Collovà E, Puglisi F, Cretella E, et al. Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs Weekly Intravenous Paclitaxel in Patients With Estrogen Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: Final Results From the Phase 2 METEORA-II Randomized Clinical Trial. Jama Oncology. PMID 37440239 DOI: 10.1001/jamaoncol.2023.2150 |
0.476 |
|
| 2023 |
Tierno D, Grassi G, Scomersi S, Bortul M, Generali D, Zanconati F, Scaggiante B. Next-Generation Sequencing and Triple-Negative Breast Cancer: Insights and Applications. International Journal of Molecular Sciences. 24. PMID 37298642 DOI: 10.3390/ijms24119688 |
0.408 |
|
| 2023 |
Bortul M, Giudici F, Tierno D, Generali D, Scomersi S, Grassi G, Bottin C, Cappelletti MR, Zanconati F, Scaggiante B. A Case-Control Study by ddPCR of ALU 260/111 and LINE-1 266/97 Copy Number Ratio in Circulating Cell-Free DNA in Plasma Revealed LINE-1 266/97 as a Potential Biomarker for Early Breast Cancer Detection. International Journal of Molecular Sciences. 24. PMID 37239866 DOI: 10.3390/ijms24108520 |
0.355 |
|
| 2023 |
Zattarin E, Presti D, Mariani L, Sposetti C, Leporati R, Menichetti A, Corti C, Benvenuti C, Fucà G, Lobefaro R, Ligorio F, Provenzano L, Vingiani A, Del Vecchio M, Griguolo G, ... ... Generali D, et al. Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors. Npj Breast Cancer. 9: 27. PMID 37069173 DOI: 10.1038/s41523-023-00534-1 |
0.496 |
|
| 2023 |
Rassy E, Garberis I, Tran-Dien A, Job B, Chung-Scott V, Bouakka I, Bassil J, Ferkh R, Lacroix-Triki M, Zanconati F, Giudici F, Generali D, Rouleau E, Lacroix L, Andre F, et al. Comparative genomic profiling of second breast cancers following first ipislateral hormone receptor-positive breast cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 36805183 DOI: 10.1158/1078-0432.CCR-22-2883 |
0.539 |
|
| 2023 |
De Paolis E, Paris I, Tilocca B, Roncada P, Foca L, Tiberi G, D'Angelo T, Pavese F, Muratore M, Carbognin L, Garganese G, Masetti R, Di Leone A, Fabi A, Scambia G, ... ... Generali D, et al. Assessing the pathogenicity of variants of unknown significance: Relevance and challenges for breast cancer precision medicine. Frontiers in Oncology. 12: 1053035. PMID 36741700 DOI: 10.3389/fonc.2022.1053035 |
0.49 |
|
| 2023 |
Tagliamento M, Gennari A, Lambertini M, Salazar R, Harbeck N, Del Mastro L, Aguilar-Company J, Bower M, Sharkey R, Dalla Pria A, Plaja A, Jackson A, Handford J, Sita-Lumsden A, Martinez-Vila C, ... ... Generali D, et al. Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2201667. PMID 36720089 DOI: 10.1200/JCO.22.01667 |
0.39 |
|
| 2022 |
Corona SP, Giudici F, Jerusalem G, Ciruelos E, Strina C, Sirico M, Bernocchi O, Milani M, Dester M, Ziglioli N, Barbieri G, Cervoni V, Montemurro F, Generali D. Addendum: Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: a retrospective exploratory analysis of the BALLET study. Oncotarget. 13: 1307. PMID 36473136 DOI: 10.18632/oncotarget.28317 |
0.775 |
|
| 2022 |
West T, Cavallero C, Ceccherini R, Foladore S, Generali D, Versace F, Scaggiante B. Impact of psychosocial, behavioral and lifestyle factors on subjective cognitive complaints and perceived quality of life in a large cohort of Italian breast cancer patients. Frontiers in Psychology. 13: 1015573. PMID 36438336 DOI: 10.3389/fpsyg.2022.1015573 |
0.37 |
|
| 2022 |
Buono G, Arpino G, Del Mastro L, Fabi A, Generali D, Puglisi F, Zambelli A, Cinieri S, Nuzzo F, Di Lauro V, Vigneri P, Bianchini G, Montemurro F, Gennari A, De Laurentiis M. Extended adjuvant endocrine treatment for premenopausal women: A Delphi approach to guide clinical practice. Frontiers in Oncology. 12: 1032166. PMID 36387212 DOI: 10.3389/fonc.2022.1032166 |
0.401 |
|
| 2022 |
Rocca A, Braga L, Volpe MC, Maiocchi S, Generali D. The Predictive and Prognostic Role of RAS-RAF-MEK-ERK Pathway Alterations in Breast Cancer: Revision of the Literature and Comparison with the Analysis of Cancer Genomic Datasets. Cancers. 14. PMID 36358725 DOI: 10.3390/cancers14215306 |
0.485 |
|
| 2022 |
La Verde N, Damia G, Garrone O, Santini D, Fabi A, Ciccarese M, Generali DG, Nunzi M, Poletto E, Ferraris E, Cretella E, Scandurra G, Meattini I, Bertolini AS, Cavanna L, et al. Tolerability of Eribulin and correlation between polymorphisms and neuropathy in an unselected population of female patients with metastatic breast cancer: results of the multicenter, single arm, phase IV PAINTER study. Breast Cancer Research : Bcr. 24: 71. PMID 36307826 DOI: 10.1186/s13058-022-01560-w |
0.475 |
|
| 2022 |
Pavese F, Capoluongo ED, Muratore M, Minucci A, Santonocito C, Fuso P, Concolino P, Di Stasio E, Carbognin L, Tiberi G, Garganese G, Corrado G, Di Leone A, Generali D, Fragomeni SM, et al. BRCA Mutation Status in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Pivotal Role for Treatment Decision-Making. Cancers. 14. PMID 36230495 DOI: 10.3390/cancers14194571 |
0.383 |
|
| 2022 |
Schettini F, Venturini S, Giuliano M, Lambertini M, Pinato DJ, Onesti CE, De Placido P, Harbeck N, Lüftner D, Denys H, Van Dam P, Arpino G, Zaman K, Mustacchi G, Gligorov J, ... ... Generali D, et al. Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer. Cancer Treatment Reviews. 111: 102468. PMID 36202026 DOI: 10.1016/j.ctrv.2022.102468 |
0.358 |
|
| 2022 |
Fabi A, Buono G, Bria E, Bianchini G, Curigliano G, De Laurentiis M, De Placido S, Del Mastro L, Guarneri V, Generali D, Livi L, Lorusso V, Montemurro F, Puglisi F, Vigneri P, et al. Controversial topics in metastatic HR+/HER2- breast cancer: Guiding treatment by a modified Delphi approach. Frontiers in Oncology. 12: 950861. PMID 36158652 DOI: 10.3389/fonc.2022.950861 |
0.412 |
|
| 2022 |
De Laurentiis M, Caputo R, Mazza M, Mansutti M, Masetti R, Ballatore Z, Torrisi R, Michelotti A, Zambelli A, Ferro A, Generali D, Vici P, Coltelli L, Fabi A, Marchetti P, et al. Safety and Efficacy of Ribociclib in Combination with Letrozole in Patients with HR+, HER2- Advanced Breast Cancer: Results from the Italian Subpopulation of Phase 3b CompLEEment-1 Study. Targeted Oncology. PMID 36152144 DOI: 10.1007/s11523-022-00913-x |
0.441 |
|
| 2022 |
D'Angelo A, Giudici F, Chapman R, Darlow J, Kilili H, Sobhani N, Cinelli M, Cappelletti MR, Strina C, Milani M, Generali D. Clinico-Immunological Effects of a Single-Agent CDK4/6 Inhibitor in Advanced HR+/HER2- Breast Cancer Based on a Window of Opportunity Study. Current Issues in Molecular Biology. 44: 4255-4267. PMID 36135204 DOI: 10.3390/cimb44090292 |
0.777 |
|
| 2022 |
Badve SS, Cho S, Lu X, Cao S, Ghose S, Thike AA, Tan PH, Ocal IT, Generali D, Zanconati F, Harris AL, Ginty F, Gökmen-Polar Y. Tumor Infiltrating Lymphocytes in Multi-National Cohorts of Ductal Carcinoma In Situ (DCIS) of Breast. Cancers. 14. PMID 36010908 DOI: 10.3390/cancers14163916 |
0.554 |
|
| 2022 |
Sobhani N, Chahwan R, Roudi R, Morris R, Volinia S, Chai D, D'Angelo A, Generali D. Predictive and Prognostic Value of Non-Coding RNA in Breast Cancer. Cancers. 14. PMID 35740618 DOI: 10.3390/cancers14122952 |
0.387 |
|
| 2022 |
Göker E, Hendriks MP, van Tilburg M, Barcaru A, Mittempergher L, van Egmond A, Kleijn M, Generali D. Treatment response and 5-year distant metastasis-free survival outcome in breast cancer patients after the use of MammaPrint and BluePrint to guide preoperative systemic treatment decisions. European Journal of Cancer (Oxford, England : 1990). 167: 92-102. PMID 35421703 DOI: 10.1016/j.ejca.2022.03.003 |
0.38 |
|
| 2022 |
Gerratana L, Pierga JY, Reuben JM, Davis AA, Wehbe FH, Dirix L, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D, Grisanti S, Garcia-Saenz JA, Stebbing J, Caldas C, Gazzaniga P, ... ... Generali D, et al. Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation. The Oncologist. PMID 35278078 DOI: 10.1093/oncolo/oyac045 |
0.39 |
|
| 2022 |
Roviello G, Generali D, Sobhani N. The combination of bevacizumab with chemotherapy is more beneficial in the metastatic setting rather than in the adjuvant setting for the treatment of HER2-negative breast cancer-a commentary on the E5103 randomized phase III clinical study. Translational Cancer Research. 8: S94-S96. PMID 35117071 DOI: 10.21037/tcr.2018.10.17 |
0.468 |
|
| 2022 |
Roviello G, Generali D, Sobhani N. The combination of bevacizumab with chemotherapy is more beneficial in the metastatic setting rather than in the adjuvant setting for the treatment of HER2-negative breast cancer-a commentary on the E5103 randomized phase III clinical study. Translational Cancer Research. 8: S94-S96. PMID 35117071 DOI: 10.21037/tcr.2018.10.17 |
0.468 |
|
| 2021 |
Bouchè V, Aldegheri G, Donofrio CA, Fioravanti A, Roberts-Thomson S, Fox SB, Schettini F, Generali D. BRAF Signaling Inhibition in Glioblastoma: Which Clinical Perspectives? Frontiers in Oncology. 11: 772052. PMID 34804975 DOI: 10.3389/fonc.2021.772052 |
0.478 |
|
| 2021 |
Garrigós L, Saura C, Martinez-Vila C, Zambelli A, Bower M, Pistilli B, Lambertini M, Ottaviani D, Diamantis N, Lumsden A, Pernas S, Generali D, Seguí E, Viñas G, Felip E, et al. COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry. Therapeutic Advances in Medical Oncology. 13: 17588359211053416. PMID 34777582 DOI: 10.1177/17588359211053416 |
0.767 |
|
| 2021 |
Pinato DJ, Tabernero J, Bower M, Scotti L, Patel M, Colomba E, Dolly S, Loizidou A, Chester J, Mukherjee U, Zambelli A, Dalla Pria A, Aguilar-Company J, Ottaviani D, Chowdhury A, ... ... Generali D, et al. Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study. The Lancet. Oncology. PMID 34741822 DOI: 10.1016/S1470-2045(21)00573-8 |
0.33 |
|
| 2021 |
Sobhani N, Roviello G, D'Angelo A, Roudi R, Neeli PK, Generali D. p53 Antibodies as a Diagnostic Marker for Cancer: A Meta-Analysis. Molecules (Basel, Switzerland). 26. PMID 34684792 DOI: 10.3390/molecules26206215 |
0.333 |
|
| 2021 |
Cazzaniga ME, Vallini I, Montagna E, Amoroso D, Berardi R, Butera A, Cagossi K, Cavanna L, Ciccarese M, Cinieri S, Cretella E, De Conciliis E, Febbraro A, Ferraù F, Ferzi A, ... ... Generali D, et al. Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study. Breast Cancer Research and Treatment. PMID 34546500 DOI: 10.1007/s10549-021-06375-5 |
0.542 |
|
| 2021 |
Schettini F, Giuliano M, Lambertini M, Bartsch R, Pinato DJ, Onesti CE, Harbeck N, Lüftner D, Rottey S, van Dam PA, Zaman K, Mustacchi G, Gligorov J, Awada A, Campone M, ... ... Generali D, et al. Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer. Cancers. 13. PMID 34503231 DOI: 10.3390/cancers13174421 |
0.446 |
|
| 2021 |
Schettini F, Corona SP, Giudici F, Strina C, Sirico M, Bernocchi O, Milani M, Ziglioli N, Aguggini S, Azzini C, Barbieri G, Cervoni V, Cappelletti MR, Molteni A, Lazzari MC, ... ... Generali D, et al. Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity Trial. Frontiers in Oncology. 11: 686776. PMID 34262869 DOI: 10.3389/fonc.2021.686776 |
0.75 |
|
| 2021 |
Pizzuti L, Barba M, Mazzotta M, Krasniqi E, Maugeri-Saccà M, Gamucci T, Berardi R, Livi L, Ficorella C, Natoli C, Cortesi E, Generali D, La Verde N, Cassano A, Bria E, et al. The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial. Scientific Reports. 11: 13770. PMID 34215766 DOI: 10.1038/s41598-021-92774-z |
0.501 |
|
| 2021 |
Guarneri V, Dieci MV, Griguolo G, Miglietta F, Girardi F, Bisagni G, Generali DG, Cagossi K, Sarti S, Frassoldati A, Gianni L, Cavanna L, Pinotti G, Musolino A, Piacentini F, et al. Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial. European Journal of Cancer (Oxford, England : 1990). 153: 133-141. PMID 34153715 DOI: 10.1016/j.ejca.2021.05.018 |
0.446 |
|
| 2021 |
Ianza A, Sirico M, Bernocchi O, Generali D. Role of the IGF-1 Axis in Overcoming Resistance in Breast Cancer. Frontiers in Cell and Developmental Biology. 9: 641449. PMID 33829018 DOI: 10.3389/fcell.2021.641449 |
0.365 |
|
| 2021 |
Schettini F, Conte B, Buono G, De Placido P, Parola S, Griguolo G, Fabi A, Bighin C, Riccardi F, Cianniello D, De Laurentiis M, Puglisi F, Pelizzari G, Bonotto M, Russo S, ... ... Generali D, et al. T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study. Esmo Open. 6: 100099. PMID 33819752 DOI: 10.1016/j.esmoop.2021.100099 |
0.423 |
|
| 2021 |
Schettini F, Giuliano M, Giudici F, Conte B, De Placido P, Venturini S, Rognoni C, Di Leo A, Locci M, Jerusalem G, Del Mastro L, Puglisi F, Conte P, De Laurentiis M, Pusztai L, ... ... Generali D, et al. Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis. Cancers. 13. PMID 33810205 DOI: 10.3390/cancers13061458 |
0.344 |
|
| 2021 |
Vernieri C, Nichetti F, Lalli L, Moscetti L, Giorgi CA, Griguolo G, Marra A, Randon G, Rea CG, Ligorio F, Scagnoli S, De Angelis C, Molinelli C, Fabbri A, Ferraro E, ... ... Generali D, et al. Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer (EVERMET). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33785482 DOI: 10.1158/1078-0432.CCR-20-4928 |
0.499 |
|
| 2021 |
Bernocchi O, Sirico M, Corona SP, Strina C, Milani M, Cappelletti MR, Ferrero G, Ziglioli N, Cervoni V, Macchiavelli A, Roviello G, Generali D. Tumor Type Agnostic Therapy Carrying BRAF Mutation: Case Reports and Review of Literature. Pharmaceuticals (Basel, Switzerland). 14. PMID 33669326 DOI: 10.3390/ph14020159 |
0.666 |
|
| 2021 |
Iacuzzo C, Giudici F, Scomersi S, Ceccherini R, Zanconati F, Generali D, Bortul M. Direct comparison of three different mathematical models in two independent datasets of EUSOMA certified centers to predict recurrence and survival in estrogen receptor-positive breast cancer: impact on clinical practice. Breast Cancer Research and Treatment. 187: 455-465. PMID 33646494 DOI: 10.1007/s10549-021-06144-4 |
0.419 |
|
| 2021 |
Griguolo G, Dieci MV, Paré L, Miglietta F, Generali DG, Frassoldati A, Cavanna L, Bisagni G, Piacentini F, Tagliafico E, Cagossi K, Ficarra G, Prat A, Conte P, Guarneri V. Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer. Npj Breast Cancer. 7: 12. PMID 33579951 DOI: 10.1038/s41523-021-00223-x |
0.387 |
|
| 2021 |
Sobhani N, Fassl A, Mondani G, Generali D, Otto T. Targeting Aberrant FGFR Signaling to Overcome CDK4/6 Inhibitor Resistance in Breast Cancer. Cells. 10. PMID 33535617 DOI: 10.3390/cells10020293 |
0.406 |
|
| 2021 |
Iacuzzo C, Giudici F, Scomersi S, Zanconati F, Ceccherini R, Bortul M, Generali D. Clinical application of mathematical calculators to predict recurrence and survival in luminal breast cancer: a retrospective analysis from two independent datasets of EUSOMA certified centers European Journal of Surgical Oncology. 47: e3. DOI: 10.1016/J.EJSO.2020.11.152 |
0.453 |
|
| 2020 |
Bon G, Pizzuti L, Laquintana V, Loria R, Porru M, Marchiò C, Krasniqi E, Barba M, Maugeri-Saccà M, Gamucci T, Berardi R, Livi L, Ficorella C, Natoli C, Cortesi E, ... Generali D, et al. Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study. Journal of Experimental & Clinical Cancer Research : Cr. 39: 279. PMID 33302999 DOI: 10.1186/s13046-020-01797-3 |
0.385 |
|
| 2020 |
Sirico M, Bernocchi O, Sobhani N, Giudici F, Corona SP, Vernieri C, Nichetti F, Cappelletti MR, Milani M, Strina C, Cervoni V, Barbieri G, Ziglioli N, Dester M, Bianchi GV, ... ... Generali D, et al. Early Changes of the Standardized Uptake Values (SUV) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer. Cancers. 12. PMID 33182575 DOI: 10.3390/cancers12113314 |
0.726 |
|
| 2020 |
Schettini F, Sobhani N, Ianza A, Triulzi T, Molteni A, Lazzari MC, Strina C, Milani M, Corona SP, Sirico M, Bernocchi O, Giudici F, Cappelletti MR, Ciruelos E, Jerusalem G, ... ... Generali D, et al. Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study. Breast Cancer Research and Treatment. PMID 32770287 DOI: 10.1007/s10549-020-05856-3 |
0.806 |
|
| 2020 |
Magbanua MJM, Hendrix LH, Hyslop T, Barry WT, Winer EP, Hudis C, Toppmeyer D, Carey LA, Partridge AH, Pierga JY, Fehm T, Vidal-Martínez J, Mavroudis D, Garcia-Saenz JA, Stebbing J, ... ... Generali D, et al. Serial analysis of circulating tumor cells in metastatic breast cancer receiving first-line chemotherapy. Journal of the National Cancer Institute. PMID 32770247 DOI: 10.1093/Jnci/Djaa113 |
0.511 |
|
| 2020 |
Pinato DJ, Zambelli A, Aguilar-Company J, Bower M, Sng CC, Salazar R, Bertuzzi A, Brunet J, Mesía R, Seguì E, Biello F, Generali D, Grisanti S, Rizzo G, Libertini M, et al. Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients. Cancer Discovery. PMID 32737082 DOI: 10.1158/2159-8290.CD-20-0773 |
0.353 |
|
| 2020 |
Corona SP, Giudici F, Jerusalem G, Ciruelos E, Strina C, Sirico M, Bernocchi O, Milani M, Dester M, Ziglioli N, Barbieri G, Cervoni V, Montemurro F, Generali D. Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: a retrospective exploratory analysis of the BALLET study. Oncotarget. 11: 2172-2181. PMID 32577163 DOI: 10.18632/oncotarget.27612 |
0.782 |
|
| 2020 |
Ianza A, Giudici F, Pinello C, Corona SP, Strina C, Bernocchi O, Bortul M, Milani M, Sirico M, Allevi G, Aguggini S, Cocconi A, Azzini C, Dester M, Cervoni V, ... ... Generali D, et al. ΔKi67 proliferation index as independent predictive and prognostic factor of outcome in luminal breast cancer: data from neoadjuvant letrozole-based treatment. Tumour Biology : the Journal of the International Society For Oncodevelopmental Biology and Medicine. 42: 1010428320925301. PMID 32489146 DOI: 10.1177/1010428320925301 |
0.781 |
|
| 2020 |
Schettini F, Giudici F, Giuliano M, Cristofanilli M, Arpino G, Del Mastro L, Puglisi F, De Placido S, Paris I, De Placido P, Venturini S, De Laurentis M, Conte P, Juric D, Llombart-Cussac A, ... ... Generali D, et al. Overall survival of CDK4/6-inhibitors-based treatments in clinically relevant subgroups of metastatic breast cancer: systematic review and meta-analysis. Journal of the National Cancer Institute. PMID 32407488 DOI: 10.1093/jnci/djaa071 |
0.484 |
|
| 2020 |
Cazzaniga ME, Verusio C, Ciccarese M, Fumagalli A, Sartori D, Valerio MR, Airoldi M, Moretti G, Ficorella C, Gianni L, Michelotti A, Zambelli A, Febbraro A, Generali D, Pistelli M, et al. Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies. Breast Care (Basel, Switzerland). 15: 30-37. PMID 32231495 DOI: 10.1159/000495469 |
0.463 |
|
| 2020 |
Navid S, Fan C, O Flores-Villanueva P, Generali D, Li Y. The Fibroblast Growth Factor Receptors in Breast Cancer: from Oncogenesis to Better Treatments. International Journal of Molecular Sciences. 21. PMID 32188012 DOI: 10.3390/ijms21062011 |
0.468 |
|
| 2020 |
Ciruelos E, Jerusalem G, Martin M, Tjan-Heijnen VCG, Neven P, Gavila J, Montemurro F, Generali D, Lang I, Martínez-Serrano MJ, Perelló MF, Conte P. Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET population. Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. PMID 32170637 DOI: 10.1007/s12094-020-02327-5 |
0.492 |
|
| 2020 |
Corona SP, Bortul M, Scomersi S, Bigal C, Bottin C, Zanconati F, Fox SB, Giudici F, Generali D. Management of the axilla in breast cancer: outcome analysis in a series of ductal versus lobular invasive cancers. Breast Cancer Research and Treatment. PMID 32060782 DOI: 10.1007/s10549-020-05565-x |
0.579 |
|
| 2020 |
Guarneri V, Dieci MV, Bisagni G, Generali DG, Cagossi K, Sarti S, Frassoldati A, Gianni L, Cavanna L, Pinotti G, Musolino A, Piacentini F, Michelotti A, Cinieri S, Griguolo G, et al. Survival analysis of the prospective randomized Cher-Lob study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer (BC). Journal of Clinical Oncology. 38: 582-582. DOI: 10.1200/jco.2020.38.15_suppl.582 |
0.431 |
|
| 2020 |
Scaggiante B, Giudici F, Zanconati F, Bottin C, Revoltella C, Corona S, Cappelletti M, Generali D, Bortul M. Evaluation of circulating cell-free DNA and its integrity as a potential predictive biomarker of breast cancer onset: A pilot study European Journal of Cancer. 138: S71-S72. DOI: 10.1016/s0959-8049(20)30719-x |
0.409 |
|
| 2020 |
Vernieri C, Nichetti F, Guarneri V, Cortesi E, Moscetti L, Del Mastro L, Fabbri A, Curigliano G, Montemurro F, Losurdo A, Generali D, Fabi A, Pedersini R, Ciccarese M, Rocca A, et al. 339P Impact of blood glucose levels on the efficacy of everolimus-exemestane in patients with advanced HR-positive/HER2 negative breast cancer: The EVERMET study Annals of Oncology. 31: S382-S383. DOI: 10.1016/j.annonc.2020.08.441 |
0.452 |
|
| 2020 |
Zattarin E, Fabbroni C, Ligorio F, Marra A, Corti C, Bernocchi O, Sirico M, Generali D, Curigliano G, Bianchi G, Capri G, Rivoltini L, De Braud F, Vernieri C. 300P Association between the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios and efficacy of CDK 4/6 inhibitors in advanced breast cancer: The observational multicenter Italian PALMARES study Annals of Oncology. 31: S362-S363. DOI: 10.1016/j.annonc.2020.08.402 |
0.438 |
|
| 2019 |
Cretella D, Fumarola C, Bonelli M, Alfieri R, La Monica S, Digiacomo G, Cavazzoni A, Galetti M, Generali D, Petronini PG. Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells. Scientific Reports. 9: 13014. PMID 31506466 DOI: 10.1038/s41598-019-49484-4 |
0.378 |
|
| 2019 |
Giuliano M, Schettini F, Rognoni C, Milani M, Jerusalem G, Bachelot T, De Laurentiis M, Thomas G, De Placido P, Arpino G, De Placido S, Cristofanilli M, Giordano A, Puglisi F, Pistilli B, ... ... Generali D, et al. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. The Lancet. Oncology. PMID 31494037 DOI: 10.1016/S1470-2045(19)30420-6 |
0.752 |
|
| 2019 |
Cazzaniga ME, Pinotti G, Montagna E, Amoroso D, Berardi R, Butera A, Cagossi K, Cavanna L, Ciccarese M, Cinieri S, Cretella E, De Conciliis E, Febbraro A, Ferraù F, Ferzi A, ... ... Generali D, et al. Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study. Breast (Edinburgh, Scotland). 48: 7-16. PMID 31470257 DOI: 10.1016/j.breast.2019.07.006 |
0.434 |
|
| 2019 |
Di Cosimo S, La Verde N, Moretti A, Cazzaniga ME, Generali D, Bianchi GV, Mariani L, Torri V, Crippa F, Paolini B, Scaperrotta G, De Santis MC, Di Nicola M, Apolone G, Gulino A, et al. Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study. Plos One. 14: e0220644. PMID 31390375 DOI: 10.1371/journal.pone.0220644 |
0.531 |
|
| 2019 |
Pizzuti L, Krasniqi E, Barchiesi G, Della Giulia M, Izzo F, Sanguineti G, Marchetti P, Mazzotta M, Giusti R, Botticelli A, Gamucci T, Natoli C, Grassadonia A, Tinari N, Iezzi L, ... ... Generali D, et al. Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting. International Journal of Cancer. PMID 31330065 DOI: 10.1002/ijc.32583 |
0.42 |
|
| 2019 |
Alborelli I, Generali D, Jermann P, Cappelletti MR, Ferrero G, Scaggiante B, Bortul M, Zanconati F, Nicolet S, Haegele J, Bubendorf L, Aceto N, Scaltriti M, Mucci G, Quagliata L, et al. Cell-free DNA analysis in healthy individuals by next-generation sequencing: a proof of concept and technical validation study. Cell Death & Disease. 10: 534. PMID 31296838 DOI: 10.1038/s41419-019-1770-3 |
0.313 |
|
| 2019 |
Cazzaniga ME, Biganzoli L, Cortesi L, De Placido S, Donadio M, Fabi A, Ferro A, Generali D, Lorusso V, Milani A, Montagna E, Munzone E, Orlando L, Pizzuti L, Simoncini E, et al. Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is the future? Oncotargets and Therapy. 12: 2989-2997. PMID 31114242 DOI: 10.2147/OTT.S189163 |
0.522 |
|
| 2019 |
Corona SP, Roviello G, Strina C, Milani M, Madaro S, Zanoni D, Allevi G, Aguggini S, Cappelletti MR, Francaviglia M, Azzini C, Cocconi A, Sirico M, Bortul M, Zanconati F, ... ... Generali D, et al. Efficacy of extended aromatase inhibitors for hormone-receptor-positive breast cancer: A literature-based meta-analysis of randomized trials. Breast (Edinburgh, Scotland). 46: 19-24. PMID 31051411 DOI: 10.1016/j.breast.2019.04.004 |
0.769 |
|
| 2019 |
Sobhani N, D'Angelo A, Pittacolo M, Roviello G, Miccoli A, Corona SP, Bernocchi O, Generali D, Otto T. Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer. Cells. 8. PMID 30959874 DOI: 10.3390/cells8040321 |
0.441 |
|
| 2019 |
Cristofanilli M, Pierga JY, Reuben J, Rademaker A, Davis AA, Peeters DJ, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D, Grisanti S, Giuliano M, Garcia-Saenz JA, Stebbing J, Caldas C, ... ... Generali D, et al. The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. Critical Reviews in Oncology/Hematology. 134: 39-45. PMID 30771872 DOI: 10.1016/J.Critrevonc.2018.12.004 |
0.696 |
|
| 2019 |
Corona SP, Sobhani N, Ianza A, Roviello G, Mustacchi G, Bortul M, Zanconati F, Generali D. Erratum to: Advances in systemic therapy for metastatic breast cancer: future perspectives. Medical Oncology (Northwood, London, England). 34: 130. PMID 28616710 DOI: 10.1007/s12032-017-0989-z |
0.485 |
|
| 2019 |
Dieci MV, Frassoldati A, Generali D, Bisagni G, Piacentini F, Cavanna L, Cagossi K, Puglisi F, Michelotti A, Berardi R, Banna G, Goubar A, Ficarra G, Griguolo G, Conte P, et al. Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trials. Breast Cancer Research and Treatment. 163: 637. PMID 28374322 DOI: 10.1007/s10549-017-4219-3 |
0.51 |
|
| 2019 |
De Laurentiis M, Mazza M, Mansutti M, Masetti R, Ballatore Z, Torrisi R, Michelotti A, Zambelli A, Ferro A, Generali D, Vici P, Coltelli L, Fabi A, Marchetti P, Ballestrero A, et al. Safety and efficacy of ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): Interim results from the Italian cohort of the CompLEEment-1 (C-1) study Annals of Oncology. 30: v119. DOI: 10.1093/annonc/mdz242.030 |
0.384 |
|
| 2019 |
Griguolo G, Dieci M, Paré L, Miglietta F, Generali D, Frassoldati A, Bisagni G, Piacentini F, Tagliafico E, Cagossi K, Ficarra G, Prat A, Conte P, Guarneri V. Immune infiltrate composition across intrinsic subtypes in hormone receptor (HR)+/HER2- early breast cancer (BC) enrolled in the prospective LETLOB trial Annals of Oncology. 30: v81. DOI: 10.1093/annonc/mdz240.068 |
0.452 |
|
| 2018 |
Sobhani N, Generali D, Zanconati F, Bortul M, Scaggiante B. Current status of PI3K-mTOR inhibition in hormone-receptor positive, HER2-negative breast cancer. World Journal of Clinical Oncology. 9: 172-179. PMID 30622925 DOI: 10.5306/wjco.v9.i8.172 |
0.447 |
|
| 2018 |
Cazzaniga M, Verusio C, Ciccarese M, Fumagalli A, Sartori D, Valerio MR, Airoldi M, Moretti G, Ficorella C, Arcangeli V, Diodati L, Zambelli A, Febbraro A, Generali D, Pistelli M, et al. Correction 2: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study. Oncotarget. 9: 36720-36721. PMID 30613355 DOI: 10.18632/oncotarget.26431 |
0.401 |
|
| 2018 |
Triulzi T, Regondi V, De Cecco L, Cappelletti MR, Di Modica M, Paolini B, Lollini PL, Di Cosimo S, Sfondrini L, Generali D, Tagliabue E. Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit. British Journal of Cancer. PMID 30478407 DOI: 10.1038/s41416-018-0318-0 |
0.479 |
|
| 2018 |
Cazzaniga M, Verusio C, Ciccarese M, Fumagalli A, Sartori D, Valerio MR, Airoldi M, Moretti G, Ficorella C, Arcangeli V, Diodati L, Zambelli A, Febbraro A, Generali D, Pistelli M, et al. Correction: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study. Oncotarget. 9: 34639-34640. PMID 30349655 DOI: 10.18632/oncotarget.26213 |
0.401 |
|
| 2018 |
Cazzaniga M, Verusio C, Ciccarese M, Fumagalli A, Sartori D, Ancona C, Airoldi M, Moretti G, Ficorella C, Arcangeli V, Diodati L, Zambelli A, Febbraro A, Generali D, Pistelli M, et al. Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study. Oncotarget. 9: 31877-31887. PMID 30159129 DOI: 10.18632/oncotarget.25874 |
0.416 |
|
| 2018 |
Sobhani N, Ianza A, D'Angelo A, Roviello G, Giudici F, Bortul M, Zanconati F, Bottin C, Generali D. Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer. Cells. 7. PMID 30011957 DOI: 10.3390/cells7070076 |
0.427 |
|
| 2018 |
Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, Toi M, Garcia-Saenz JA, Hartkopf A, Generali D, Rothé F, et al. Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis. Journal of the National Cancer Institute. PMID 29659933 DOI: 10.1093/Jnci/Djy018 |
0.672 |
|
| 2018 |
Sobhani N, Generali D, Zanconati F, Bortul M, Scaggiante B. Cell-free DNA integrity for the monitoring of breast cancer: Future perspectives? World Journal of Clinical Oncology. 9: 26-32. PMID 29651384 DOI: 10.5306/wjco.v9.i2.26 |
0.382 |
|
| 2018 |
Corona SP, Generali D. Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2- advanced breast cancer. Drug Design, Development and Therapy. 12: 321-330. PMID 29497278 DOI: 10.2147/DDDT.S137783 |
0.394 |
|
| 2018 |
Sobhani N, Roviello G, Corona SP, Scaltriti M, Ianza A, Bortul M, Zanconati F, Generali D. The prognostic value of PI3K mutational status in breast cancer: A meta-analysis. Journal of Cellular Biochemistry. 119: 4287-4292. PMID 29345357 DOI: 10.1002/jcb.26687 |
0.459 |
|
| 2018 |
Generali D, Corona SP, Pusztai L, Rouzier R, Allevi G, Aguggini S, Milani M, Strina C, Frati A. Benefit of the addition of hormone therapy to neoadjuvant anthracycline-based chemotherapy for breast cancer: comparison of predicted and observed pCR. Journal of Cancer Research and Clinical Oncology. 144: 601-606. PMID 29344722 DOI: 10.1007/s00432-017-2574-4 |
0.78 |
|
| 2018 |
Davis AA, Pierga J, Dirix LY, Michiels S, Rademaker A, Reuben JM, Fehm TN, Munzone E, Giuliano M, Vidal-Martinez J, Mavroudis D, Grisanti S, Generali DG, Garcia-Saenz JA, Stebbing J, et al. The impact of circulating tumor cells (CTCs) detection in metastatic breast cancer (MBC): Implications of “indolent” stage IV disease (Stage IVindolent). Journal of Clinical Oncology. 36: 1019-1019. DOI: 10.1200/Jco.2018.36.15_Suppl.1019 |
0.381 |
|
| 2018 |
Göker E, De Roos M, Hendriks M, Van Tilburg M, Dreezen C, Stork-Sloots L, Van Egmond A, Neijenhuis S, Generali D. Chemosensitivity and endocrine sensitivity predicted by combining the 80-gene signature and 70-gene signature in the prospective Neoadjuvant Breast Registry Europe – Symphony Trial (NBREaST II) European Journal of Cancer. 92: S145. DOI: 10.1016/s0959-8049(18)30659-2 |
0.302 |
|
| 2017 |
Norouzi S, Majeed M, Pirro M, Generali D, Sahebkar A. Curcumin as an adjunct therapy and microRNA modulator in breast cancer. Current Pharmaceutical Design. PMID 29189128 DOI: 10.2174/1381612824666171129203506 |
0.475 |
|
| 2017 |
Fabi A, Giannarelli D, Moscetti L, Santini D, Zambelli A, Laurentiis M, Caruso M, Generali D, Valle E, Leonardi V, Cannita K, Arpino G, Filippelli G, Ferretti G, Giampaglia M, et al. Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter? Future Oncology (London, England). 13: 2791-2797. PMID 29182361 DOI: 10.2217/fon-2017-0336 |
0.403 |
|
| 2017 |
Corona SP, Roviello G, Strina C, Milani M, Allevi G, Aguggini S, Zanoni D, Generali D. Could gonadotropin-releasing hormone analogs be helpful in the treatment of triple-negative breast cancer? Future Oncology (London, England). 13: 2473-2477. PMID 29121807 DOI: 10.2217/fon-2017-0272 |
0.778 |
|
| 2017 |
Milani M, Venturini S, Bonardi S, Allevi G, Strina C, Cappelletti MR, Corona SP, Aguggini S, Bottini A, Berruti A, Jubb A, Campo L, Harris AL, Gatter K, Fox SB, ... Generali D, et al. Hypoxia-related biological markers as predictors of epirubicin-based treatment responsiveness and resistance in locally advanced breast cancer. Oncotarget. 8: 78870-78881. PMID 29108271 DOI: 10.18632/oncotarget.20239 |
0.85 |
|
| 2017 |
Fabi A, De Laurentiis M, Caruso M, Valle E, Moscetti L, Santini D, Cannita K, Carbognin L, Ciccarese M, Rossello R, Arpino G, Leonardi V, Montemurro F, Verde N, Generali D, et al. Efficacy and safety of T-DM1 in the 'common-practice' of HER2+ advanced breast cancer setting: a multicenter study. Oncotarget. 8: 64481-64489. PMID 28969087 DOI: 10.18632/oncotarget.16373 |
0.384 |
|
| 2017 |
Cazzaniga ME, Airoldi M, Arcangeli V, Artale S, Atzori F, Ballerio A, Bianchi GV, Blasi L, Campidoglio S, Ciccarese M, Cursano MC, Piezzo M, Fabi A, Ferrari L, Ferzi A, ... ... Generali D, et al. Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study. Breast (Edinburgh, Scotland). 35: 115-121. PMID 28711793 DOI: 10.1016/j.breast.2017.06.043 |
0.372 |
|
| 2017 |
Corona SP, Sobhani N, Ianza A, Roviello G, Mustacchi G, Bortul M, Zanconati F, Generali D. Advances in systemic therapy for metastatic breast cancer: future perspectives. Medical Oncology (Northwood, London, England). 34: 119. PMID 28526922 DOI: 10.1007/s12032-017-0975-5 |
0.445 |
|
| 2017 |
Generali D, Montemurro F, Bordonaro R, Mafodda A, Romito S, Michelotti A, Piovano P, Ionta MT, Bighin C, Sartori D, Frassoldati A, Cazzaniga ME, Riccardi F, Testore F, Vici P, et al. Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting. The Oncologist. PMID 28432226 DOI: 10.1634/theoncologist.2016-0461 |
0.512 |
|
| 2017 |
Fabi A, De Laurentiis M, Caruso M, Valle E, Moscetti L, Santini D, Cannita K, Carbognin L, Ciccarese M, Rossello R, Arpino G, Leonardi V, Montemurro F, La Verde N, Generali D, et al. Efficacy and safety of T-DM1 in the 'common-practice' of HER2+ advanced breast cancer setting: a multicenter study. Oncotarget. PMID 28415567 DOI: 10.18632/oncotarget.16373 |
0.384 |
|
| 2017 |
Ravelli A, Roviello G, Cretella D, Cavazzoni A, Biondi A, Cappelletti MR, Zanotti L, Ferrero G, Ungari M, Zanconati F, Bottini A, Alfieri R, Petronini PG, Generali D. Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility. Tumour Biology : the Journal of the International Society For Oncodevelopmental Biology and Medicine. 39: 1010428317695023. PMID 28378631 DOI: 10.1177/1010428317695023 |
0.384 |
|
| 2017 |
Corona SP, Ravelli A, Cretella D, Cappelletti MR, Zanotti L, Dester M, Gobbi A, Petronini PG, Generali D. CDK4/6 inhibitors in HER2-positive breast cancer. Critical Reviews in Oncology/Hematology. 112: 208-214. PMID 28325261 DOI: 10.1016/j.critrevonc.2017.02.022 |
0.502 |
|
| 2017 |
Dieci MV, Frassoldati A, Generali D, Bisagni G, Piacentini F, Cavanna L, Cagossi K, Puglisi F, Michelotti A, Berardi R, Banna G, Goubar A, Ficarra G, Griguolo G, Conte P, et al. Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trials. Breast Cancer Research and Treatment. 163: 295-302. PMID 28289852 DOI: 10.1007/s10549-017-4191-y |
0.451 |
|
| 2017 |
Roviello G, Polom K, Roviello F, Marrelli D, Multari AG, Paganini G, Pacifico C, Generali D. Targeting VEGFR-2 in Metastatic Gastric Cancer: Results From a Literature-Based Meta-Analysis. Cancer Investigation. 35: 187-194. PMID 28165839 DOI: 10.1080/07357907.2016.1276185 |
0.321 |
|
| 2017 |
Mustacchi G, Generali D. Cost-effectiveness and sustainability of breast cancer screening and new anti-cancer drugs. Journal of Medical Economics. 20: 405-408. PMID 28105869 DOI: 10.1080/13696998.2017.1285306 |
0.398 |
|
| 2017 |
Roviello G, Zanotti L, Correale P, Gobbi A, Wigfield S, Guglielmi A, Pacifico C, Generali D. Is still there a role for IL-2 for solid tumors other than melanoma or renal cancer? Immunotherapy. 9: 25-32. PMID 28000528 DOI: 10.2217/imt-2016-0107 |
0.731 |
|
| 2017 |
Roviello G, Pagani O, Meani F, Strina C, Zanoni D, Milani M, Sohbani N, Ianza A, Bortul M, Zanconati F, Rossellini P, Generali D. Efficacy of extended aromatase inhibitors for hormone-receptor–positive breast cancer: a literature based meta-analysis of randomized trials Annals of Oncology. 28: vi34. DOI: 10.1093/ANNONC/MDX424.031 |
0.761 |
|
| 2017 |
Di Cosimo S, Laverde N, Cazzaniga M, Generali D, Bianchi G, Tagliabue E, Torri V, Crippa F, Paolini B, Scaperrotta G, Gulino A, Tripodo C, Colombo M, Folli S, de Braud F. Neoadjuvant eribulin following anthracycline and taxane in triple negative breast cancer (HOPE): A multicenter, two stage, phase II trial Annals of Oncology. 28: v50. DOI: 10.1093/ANNONC/MDX362.019 |
0.442 |
|
| 2016 |
Dieci MV, Prat A, Tagliafico E, Paré L, Ficarra G, Bisagni G, Piacentini F, Generali DG, Conte P, Guarneri V. Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 27: 1867-73. PMID 27484801 DOI: 10.1093/annonc/mdw262 |
0.424 |
|
| 2016 |
Andreis D, Bonardi S, Allevi G, Aguggini S, Gussago F, Milani M, Strina C, Spada D, Ferrero G, Ungari M, Rocca A, Nanni O, Roviello G, Berruti A, Harris AL, ... ... Generali D, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with T2 to T4, N0 and N1 breast cancer. Breast (Edinburgh, Scotland). 29: 55-61. PMID 27428471 DOI: 10.1016/j.breast.2016.07.003 |
0.749 |
|
| 2016 |
Musolino A, Naldi N, Dieci MV, Zanoni D, Rimanti A, Boggiani D, Sgargi P, Generali DG, Piacentini F, Ambroggi M, Cagossi K, Gianni L, Sarti S, Bisagni G, Ardizzoni A, et al. Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer. The Pharmacogenomics Journal. 16: 472-7. PMID 27378608 DOI: 10.1038/tpj.2016.51 |
0.355 |
|
| 2016 |
Roviello G, Ravelli A, Ida Fiaschi A, Cappelletti MR, Gobbi A, Senti C, Zanotti L, Polom K, Reynolds AR, Fox SB, Generali D. Apatinib for the treatment of gastric cancer. Expert Review of Gastroenterology & Hepatology. PMID 27376400 DOI: 10.1080/17474124.2016.1209407 |
0.491 |
|
| 2016 |
Jerusalem G, Mariani G, Ciruelos EM, Martin M, Tjan-Heijnen VC, Neven P, Gavila JG, Michelotti A, Montemurro F, Generali D, Simoncini E, Lang I, Mardiak J, Naume B, Camozzi M, et al. Safety of Everolimus Plus Exemestane In Patients With Hormone-Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Progressing on Prior Non-Steroidal Aromatase Inhibitors: Primary Results of a Phase 3b, Open-Label, Single-Arm, Expanded-Access Multicenter Trial (BALLET). Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. PMID 27358383 DOI: 10.1093/annonc/mdw249 |
0.366 |
|
| 2016 |
Roviello G, Milani M, Gobbi A, Dester M, Cappelletti MR, Allevi G, Aguggini S, Ravelli A, Gussago F, Cocconi A, Zanotti L, Senti C, Strina C, Bottini A, Generali D. A Phase II study of olaparib in breast cancer patients: biological evaluation from a 'window of opportunity' trial. Future Oncology (London, England). PMID 27324108 DOI: 10.2217/fon-2016-0116 |
0.793 |
|
| 2016 |
Roviello G, Ravelli A, Barni S, Petrelli F, Bottini A, Fox SB, Generali D. Is it time for everolimus-based combination in castration-resistant prostate cancer? Future Oncology (London, England). PMID 27250597 DOI: 10.2217/fon-2016-0136 |
0.437 |
|
| 2016 |
Roviello G, Sigala S, Sandhu S, Bonetta A, Cappelletti MR, Zanotti L, Bottini A, Sternberg CN, Fox SB, Generali D. Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials. European Journal of Cancer (Oxford, England : 1990). 61: 111-121. PMID 27162152 DOI: 10.1016/j.ejca.2016.04.002 |
0.455 |
|
| 2016 |
Polom K, Roviello G, Generali D, Marano L, Petrioli R, Marsili S, Caputo E, Marrelli D, Roviello F. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for treatment of ovarian cancer. International Journal of Hyperthermia : the Official Journal of European Society For Hyperthermic Oncology, North American Hyperthermia Group. 1-13. PMID 26984715 DOI: 10.3109/02656736.2016.1149233 |
0.358 |
|
| 2016 |
Roviello G, Milani M, Gobbi A, Cappelletti MR, Zanotti L, Senti C, Bottini A, Strina C, Sigala S, Generali D. A Phase Ib Open-Label Study to Assess the Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-Negative Breast Cancers. Clinical Breast Cancer. PMID 26943987 DOI: 10.1016/j.clbc.2016.02.012 |
0.761 |
|
| 2016 |
Bonetta A, Bandera L, Roviello G, Cafaro I, Bottini A, Generali D. Neoadjuvant chemotherapy and radical radiotherapy associated with cetuximab for laryngeal cancer in a pancreas and renal recipient. Anti-Cancer Drugs. 27: 470-3. PMID 26908347 DOI: 10.1097/CAD.0000000000000352 |
0.365 |
|
| 2016 |
Fragni M, Bonini SA, Bettinsoli P, Bodei S, Generali D, Bottini A, Spano PF, Memo M, Sigala S. The miR-21/PTEN/Akt signaling pathway is involved in the anti-tumoral effects of zoledronic acid in human breast cancer cell lines. Naunyn-Schmiedeberg's Archives of Pharmacology. 389: 529-38. PMID 26905520 DOI: 10.1007/s00210-016-1224-8 |
0.345 |
|
| 2016 |
de Oliveira SF, Ganzinelli M, Chilà R, Serino L, Maciel ME, Urban Cde A, de Lima RS, Cavalli IJ, Generali D, Broggini M, Damia G, Ribeiro EM. Characterization of MTAP Gene Expression in Breast Cancer Patients and Cell Lines. Plos One. 11: e0145647. PMID 26751376 DOI: 10.1371/journal.pone.0145647 |
0.489 |
|
| 2016 |
Di Modica M, Sfondrini L, Regondi V, Varchetta S, Oliviero B, Mariani G, Bianchi GV, Generali D, Balsari A, Triulzi T, Tagliabue E. Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition. Oncotarget. 7: 255-65. PMID 26595802 DOI: 10.18632/oncotarget.6353 |
0.31 |
|
| 2016 |
Triulzi T, De Cecco L, Sandri M, Prat A, Giussani M, Paolini B, Carcangiu ML, Canevari S, Bottini A, Balsari A, Menard S, Generali D, Campiglio M, Di Cosimo S, Tagliabue E. Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration. Oncotarget. 6: 28173-82. PMID 26334217 DOI: 10.18632/oncotarget.4405 |
0.396 |
|
| 2016 |
Triulzi T, De Cecco L, Sandri M, Prat A, Giussani M, Paolini B, Carcangiu ML, Canevari S, Bottini A, Balsari A, Menard S, Generali D, Campiglio M, Di Cosimo S, Tagliabue E. Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration. Oncotarget. 6: 28173-82. PMID 26334217 DOI: 10.18632/oncotarget.4405 |
0.396 |
|
| 2016 |
Del Mastro L, Cazzaniga M, Solidoro P, Generali D, Bianchi G, Testore F, De Placido S. Everolimus-based therapy in patients with hormone receptor-positive, HER2(-) advanced breast cancer: management considerations. Future Oncology (London, England). 11: 2251-4. PMID 26260802 DOI: 10.2217/fon.15.134 |
0.472 |
|
| 2016 |
Fabi A, Cannita K, Ferretti G, Ciccarese M, Arpino G, Montemurro F, La Verde NM, Generali DG, Scandurra G, Filippelli G, Russillo M, Paris I, Stani S, Fabbri A, Minelli M, et al. Real-life effectiveness of T-DM1 in heavily pretreated HER2-positive advanced breast cancer patients: An Italian observational study. Journal of Clinical Oncology. 34: e12019-e12019. DOI: 10.1200/JCO.2016.34.15_SUPPL.E12019 |
0.466 |
|
| 2016 |
Bidard F, Peeters D, Fehm T, Nole F, Gisbert-Criado R, Mavroudis D, Grisanti S, Generali D, Garcia-Saenz J, Stebbing J, Caldas C, Gazzaniga P, Manso L, Zamarchi R, Lascoiti AFd, et al. Abstract P2-08-08: Circulating tumor cells count-based nomograms to predict survival of metastatic breast cancer patients: Results from the European pooled analysis Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P2-08-08 |
0.625 |
|
| 2016 |
Fabi A, Alesini D, De Laurentiis M, Valle E, Santini D, Cannita K, Carbognin L, Ciccarese M, Arpino G, Leonardi V, Montemurro F, La Verde N, Generali D, Scandurra G, Russillo M, et al. Italian observational study on T-DM1 in HER2 positive advanced breast cancer patients: real world effectiveness and safety Annals of Oncology. 27: iv61. DOI: 10.1093/annonc/mdw337.07 |
0.465 |
|
| 2016 |
Arpino G, Generali D, Sapino A, Del Mastro L, Frassoldati A, de Laurentiis M, Pronzato P, Mustacchi G, Cazzaniga M, De Placido S, Conte P, Cappelletti M, Zanoni V, Antonelli A, Martinotti M, et al. Corrigendum to "Gene expression profiling in breast cancer: A clinical perspective" [The Breast 22 (2013) 109-120 [doi:10.1016/j.breast.2013.01.016.]] Breast. 25: 86. DOI: 10.1016/j.breast.2015.11.002 |
0.484 |
|
| 2015 |
Martino M, Lanza F, Pavesi L, Öztürk M, Blaise D, Núñez RL, Schouten HC, Bosi A, De Giorgi U, Generali D, Rosti G, Necchi A, Ravelli A, Bengala C, Badoglio M, et al. High-dose chemotherapy and autologous hematopoietic stem cell transplantation as adjuvant treatment in high-risk breast cancer: data from the EBMT registry. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 26723932 DOI: 10.1016/j.bbmt.2015.12.011 |
0.347 |
|
| 2015 |
Puglisi F, Fontanella C, Amoroso V, Bianchi GV, Bisagni G, Falci C, Fontana A, Generali D, Gianni L, Grassadonia A, Moscetti L, Portarena I, Rossi E, Marchetti P. Current challenges in HER2-positive breast cancer. Critical Reviews in Oncology/Hematology. PMID 26638862 DOI: 10.1016/j.critrevonc.2015.10.016 |
0.495 |
|
| 2015 |
Roviello G, Polom K, Petrioli R, Marano L, Marrelli D, Paganini G, Savelli V, Generali D, De Franco L, Ravelli A, Roviello F. Monoclonal antibodies-based treatment in gastric cancer: current status and future perspectives. Tumour Biology : the Journal of the International Society For Oncodevelopmental Biology and Medicine. PMID 26566626 DOI: 10.1007/s13277-015-4408-9 |
0.378 |
|
| 2015 |
Ravelli A, Reuben JM, Lanza F, Anfossi S, Cappelletti MR, Zanotti L, Gobbi A, Senti C, Brambilla P, Milani M, Spada D, Pedrazzoli P, Martino M, Bottini A, Generali D, et al. Breast cancer circulating biomarkers: advantages, drawbacks, and new insights. Tumour Biology : the Journal of the International Society For Oncodevelopmental Biology and Medicine. 36: 6653-65. PMID 26307395 DOI: 10.1007/s13277-015-3944-7 |
0.747 |
|
| 2015 |
Guarneri V, Dieci MV, Frassoldati A, Maiorana A, Ficarra G, Bettelli S, Tagliafico E, Bicciato S, Generali DG, Cagossi K, Bisagni G, Sarti S, Musolino A, Ellis C, Crescenzo R, et al. Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer. The Oncologist. 20: 1001-10. PMID 26245675 DOI: 10.1634/theoncologist.2015-0138 |
0.435 |
|
| 2015 |
Cappelletti MR, Gnetti L, Santini D, Spada D, Fox SB, Generali D. Would the combination of everolimus with endocrine-therapy help in FGFR2 positive serous endometrial cancer? Oncoscience. 2: 567-9. PMID 26244161 DOI: 10.18632/ONCOSCIENCE.168 |
0.535 |
|
| 2015 |
Provenzano E, Byrne DJ, Russell PA, Wright GM, Generali D, Fox SB. Differential expression of immunohistochemical markers in primary lung and breast cancers enriched for triple-negative tumours. Histopathology. PMID 26118394 DOI: 10.1111/his.12765 |
0.603 |
|
| 2015 |
Amoroso V, Generali D, Buchholz T, Cristofanilli M, Pedersini R, Curigliano G, Daidone MG, Di Cosimo S, Dowsett M, Fox S, Harris AL, Makris A, Vassalli L, Ravelli A, Cappelletti MR, et al. International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013). Journal of the National Cancer Institute. Monographs. 2015: 90-6. PMID 26063896 DOI: 10.1093/jncimonographs/lgv023 |
0.692 |
|
| 2015 |
Pritzker K, Pritzker L, Generali D, Bottini A, Cappelletti MR, Guo B, Parissenti A, Trudeau M. RNA Disruption and Drug Response in Breast Cancer Primary Systemic Therapy. Journal of the National Cancer Institute. Monographs. 2015: 76-80. PMID 26063893 DOI: 10.1093/jncimonographs/lgv015 |
0.357 |
|
| 2015 |
Pedrazzoli P, Martino M, Delfanti S, Generali D, Rosti G, Bregni M, Lanza F. High-Dose Chemotherapy With Autologous Hematopoietic Stem Cell Transplantation for High-Risk Primary Breast Cancer. Journal of the National Cancer Institute. Monographs. 2015: 70-5. PMID 26063892 DOI: 10.1093/jncimonographs/lgv010 |
0.35 |
|
| 2015 |
Generali D, Berruti A, Cappelletti MR, Zanotti L, Brugnoli G, Forti M, Bedussi F, Vailati ME, Milani M, Strina C, Ardine M, Aguggini S, Allevi G, Ferrero G, Bertoni R, et al. Effect of Primary Letrozole Treatment on Tumor Expression of mTOR and HIF-1α and Relation to Clinical Response. Journal of the National Cancer Institute. Monographs. 2015: 64-6. PMID 26063890 DOI: 10.1093/jncimonographs/lgv018 |
0.817 |
|
| 2015 |
Generali D, Ardine M, Strina C, Milani M, Cappelletti MR, Zanotti L, Forti M, Bedussi F, Martinotti M, Amoroso V, Sigala S, Simoncini E, Berruti A, Bottini A. Neoadjuvant Treatment Approach: The Rosetta Stone for Breast Cancer? Journal of the National Cancer Institute. Monographs. 2015: 32-5. PMID 26063883 DOI: 10.1093/jncimonographs/lgv019 |
0.792 |
|
| 2015 |
Generali D, Fox SB, Cristofanilli M, Bianchini G, Zambelli A, Hatzis C, Barberis M, Tarricone R, Bottini A, Rossi C, Tringali M. Neoadjuvant Model in Cancer Treatment: From Clinical Opportunity to Health-Care Utility. Journal of the National Cancer Institute. Monographs. 2015: 1-3. PMID 26063875 DOI: 10.1093/jncimonographs/lgv022 |
0.499 |
|
| 2015 |
Generali D, Venturini S, Rognoni C, Ciani O, Pusztai L, Loi S, Jerusalem G, Bottini A, Tarricone R. A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer. Breast Cancer Research and Treatment. 152: 95-117. PMID 26044370 DOI: 10.1007/s10549-015-3453-9 |
0.391 |
|
| 2015 |
Ravelli A, Reuben JM, Lanza F, Anfossi S, Cappelletti MR, Zanotti L, Gobbi A, Milani M, Spada D, Pedrazzoli P, Martino M, Bottini A, Generali D. Immune-related strategies driving immunotherapy in breast cancer treatment: a real clinical opportunity. Expert Review of Anticancer Therapy. 15: 689-702. PMID 25927868 DOI: 10.1586/14737140.2015.1042864 |
0.73 |
|
| 2015 |
Fabi A, Moscetti L, Ciccarese M, Caramanti M, Salesi N, La Verde N, Russillo M, Generali D, Scandurra G, Vari S, Pacetti U, Cognetti F, Giannarelli D. Eribulin in heavily pretreated metastatic breast cancer patients and clinical/biological feature correlations: impact on the practice. Future Oncology (London, England). 11: 431-8. PMID 25675124 DOI: 10.2217/fon.14.271 |
0.41 |
|
| 2015 |
Bazzola L, Foroni C, Andreis D, Zanoni V, R Cappelletti M, Allevi G, Aguggini S, Strina C, Milani M, Venturini S, Ferrozzi F, Giardini R, Bertoni R, Turley H, Gatter K, ... ... Generali D, et al. Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer. British Journal of Cancer. 112: 52-60. PMID 25461806 DOI: 10.1038/bjc.2014.563 |
0.858 |
|
| 2015 |
Fina E, Callari M, Reduzzi C, D'Aiuto F, Mariani G, Generali D, Pierotti MA, Daidone MG, Cappelletti V. Gene expression profiling of circulating tumor cells in breast cancer. Clinical Chemistry. 61: 278-89. PMID 25411184 DOI: 10.1373/clinchem.2014.229476 |
0.316 |
|
| 2015 |
Generali D, Rossi C, Bottini A. Treatment decision-making in breast cancer: role of the multidisciplinary team meeting in a breast unit Breast Cancer Management. 4: 121-123. DOI: 10.2217/BMT.15.3 |
0.459 |
|
| 2015 |
Guarneri V, Dieci MV, Frassoldati A, Maiorana A, Ficarra G, Bettelli S, Tagliafico E, Bicciato S, Generali DG, Cagossi K, Bisagni G, Sarti S, Musolino A, Ellis C, Crescenzo R, et al. Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer Oncologist. 20: 1001-1010. DOI: 10.1634/theoncologist.2015-0138 |
0.457 |
|
| 2015 |
Fernandez E, Mistry H, Brightman FA, Orrell D, Generali DG, Milani M, Bottini A, Chassagnole C. From preclinical to phase II: Using virtual tumor clinical model to predict the efficacy of randomised phase II trials. Journal of Clinical Oncology. 33: e12032-e12032. DOI: 10.1200/JCO.2015.33.15_SUPPL.E12032 |
0.621 |
|
| 2015 |
Pedrazzoli P, Martino M, Delfanti S, Generali D, Rosti G, Bregni M, Lanza F. High-dose chemotherapy with autologous hematopoietic stem cell transplantation for high-risk primary breast cancer Journal of the National Cancer Institute - Monographs. 2015: 70-75. DOI: 10.1093/jncimonographs/lgv010 |
0.34 |
|
| 2015 |
Generali D, Venturini S, Rognoni C, Ciani O, Pusztai L, Loi S, Jerusalem G, Bottini A, Tarricone R. A Network Meta-Analysis of Everolimus plus Exemestane versus Chemotherapy in the First and Second Line Treatment of Estrogen Receptor Positive Metastatic Breast Cancer Annals of Oncology. 26: vi9. DOI: 10.1093/annonc/mdv336.21 |
0.47 |
|
| 2015 |
Neven P, Generali D, Ciruelos E, Lang I, Gavila J, Bighin C, Borms M, Conte P, Montemurro F, Sartori D, Lee T, Camozzi M, Lorizzo K, Ocak O, Jerusalem G. 1850 Safety of everolimus plus exemestane in elderly patients with Hormone-Receptor-Positive (HR+), HER2- locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors (NSAIs): BALLET (CRAD001YIC04) European Journal of Cancer. 51: S282. DOI: 10.1016/S0959-8049(16)30800-0 |
0.48 |
|
| 2014 |
Collovà E, Ferzi A, Scandurra G, Aurilio G, Torri V, Porcu L, Sanò MV, Taibi E, Foglietta J, Generali D, Andreis D, Dazzani MC, Bramati A, Marcon I, Atzori F, et al. Efficacy of trastuzumab in unselected patients with HER2-positive metastatic breast cancer: a retrospective analysis. Tumori. 100: 426-31. PMID 25296592 DOI: 10.1700/1636.17902 |
0.551 |
|
| 2014 |
Mohd Nafi SN, Generali D, Kramer-Marek G, Gijsen M, Strina C, Cappelletti M, Andreis D, Haider S, Li JL, Bridges E, Capala J, Ioannis R, Harris AL, Kong A. Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer. Oncotarget. 5: 5934-49. PMID 25153719 |
0.859 |
|
| 2014 |
Zanotti L, Bottini A, Rossi C, Generali D, Cappelletti MR. Diagnostic tests based on gene expression profile in breast cancer: from background to clinical use. Tumour Biology : the Journal of the International Society For Oncodevelopmental Biology and Medicine. 35: 8461-70. PMID 25048969 DOI: 10.1007/s13277-014-2366-2 |
0.385 |
|
| 2014 |
Feldinger K, Generali D, Kramer-Marek G, Gijsen M, Ng TB, Wong JH, Strina C, Cappelletti M, Andreis D, Li JL, Bridges E, Turley H, Leek R, Roxanis I, Capala J, et al. ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer. Oncotarget. 5: 6633-46. PMID 24952873 |
0.826 |
|
| 2014 |
Generali D, Buffa FM, Deb S, Cummings M, Reid LE, Taylor M, Andreis D, Allevi G, Ferrero G, Byrne D, Martinotti M, Bottini A, Harris AL, Lakhani SR, Fox SB. COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment. British Journal of Cancer. 111: 46-54. PMID 24874483 DOI: 10.1038/bjc.2014.236 |
0.617 |
|
| 2014 |
Bedussi F, Bottini A, Memo M, Fox SB, Sigala S, Generali D. Targeting fibroblast growth factor receptor in breast cancer: a promise or a pitfall? Expert Opinion On Therapeutic Targets. 18: 665-78. PMID 24833241 DOI: 10.1517/14728222.2014.898064 |
0.592 |
|
| 2014 |
Koukourakis MI, Giatromanolaki A, Bottini A, Cappelletti MR, Zanotti L, Allevi G, Strina C, Ardine M, Milani M, Brugnoli G, Martinotti M, Ferrero G, Bertoni R, Ferrozzi F, Harris AL, ... Generali D, et al. Prospective neoadjuvant analysis of PET imaging and mechanisms of resistance to Trastuzumab shows role of HIF1 and autophagy. British Journal of Cancer. 110: 2209-16. PMID 24722179 DOI: 10.1038/bjc.2014.196 |
0.813 |
|
| 2014 |
Bidard FC, Peeters DJ, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D, Grisanti S, Generali D, Garcia-Saenz JA, Stebbing J, Caldas C, Gazzaniga P, Manso L, Zamarchi R, de Lascoiti AF, et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. The Lancet. Oncology. 15: 406-14. PMID 24636208 DOI: 10.1016/S1470-2045(14)70069-5 |
0.689 |
|
| 2014 |
Guarneri V, Generali DG, Frassoldati A, Artioli F, Boni C, Cavanna L, Tagliafico E, Maiorana A, Bottini A, Cagossi K, Bisagni G, Piacentini F, Ficarra G, Bettelli S, Roncaglia E, et al. Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 1050-7. PMID 24590635 DOI: 10.1200/JCO.2013.51.4737 |
0.394 |
|
| 2014 |
Foroni C, Milan M, Strina C, Cappelletti M, Fumarola C, Bonelli M, Bertoni R, Ferrero G, Maldotti M, Takano E, Andreis D, Venturini S, Brugnoli G, Petronini PG, Zanoni V, ... ... Generali D, et al. Pure anti-tumor effect of zoledronic acid in naïve bone-only metastatic and locally advanced breast cancer: proof from the "biological window therapy". Breast Cancer Research and Treatment. 144: 113-21. PMID 24469643 DOI: 10.1007/s10549-014-2840-y |
0.532 |
|
| 2014 |
Di Cosimo S, Arpino G, Generali D. Neoadjuvant treatment of HER2 and hormone-receptor positive breast cancer - moving beyond pathological complete response. Breast (Edinburgh, Scotland). 23: 188-92. PMID 24393616 DOI: 10.1016/j.breast.2013.12.005 |
0.543 |
|
| 2014 |
La Verde N, Collovà E, Lonardi S, Generali D, Moretti A, Atzori F, Cazzaniga M, Saggia C, Tondulli L, Marcon I, Gentile AL, Rossello R, Martelli O, Aglione S, Farina G, et al. Male breast cancer: clinical features and multimodal treatment in a retrospective survey analysis at Italian centers. Tumori. 99: 596-600. PMID 24362863 DOI: 10.1700/1377.15308 |
0.528 |
|
| 2014 |
La Verde N, Collovà E, Lonardi S, Generali D, Moretti A, Atzori F, Cazzaniga M, Saggia C, Tondulli L, Marcon I, Gentile AL, Rossello R, Martelli O, Aglione S, Farina G, et al. Male breast cancer: clinical features and multimodal treatment in a retrospective survey analysis at Italian centers. Tumori. 99: 596-600. PMID 24362863 DOI: 10.1700/1377.15308 |
0.528 |
|
| 2014 |
Del Re M, Fontana A, Generali DG, Pistilli B, Citi V, Ulivi P, Zoli W, Bona E, Salvadori B, Ferrarini I, Landucci E, Fancelli S, Bertolini I, Michelotti A, Latini L, et al. Association of eNOS polymorphisms with clinical outcome in bevacizumab-treated breast cancer patients. Journal of Clinical Oncology. 32: e22075-e22075. DOI: 10.1200/JCO.2014.32.15_SUPPL.E22075 |
0.463 |
|
| 2013 |
Nikitenko LL, Leek R, Henderson S, Pillay N, Turley H, Generali D, Gunningham S, Morrin HR, Pellagatti A, Rees MC, Harris AL, Fox SB. The G-protein-coupled receptor CLR is upregulated in an autocrine loop with adrenomedullin in clear cell renal cell carcinoma and associated with poor prognosis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 5740-8. PMID 23969937 DOI: 10.1158/1078-0432.CCR-13-1712 |
0.775 |
|
| 2013 |
Fumarola C, Caffarra C, La Monica S, Galetti M, Alfieri RR, Cavazzoni A, Galvani E, Generali D, Petronini PG, Bonelli MA. Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling. Breast Cancer Research and Treatment. 141: 67-78. PMID 23963659 DOI: 10.1007/s10549-013-2668-x |
0.364 |
|
| 2013 |
Ribeiro E, Ganzinelli M, Andreis D, Bertoni R, Giardini R, Fox SB, Broggini M, Bottini A, Zanoni V, Bazzola L, Foroni C, Generali D, Damia G. Triple negative breast cancers have a reduced expression of DNA repair genes. Plos One. 8: e66243. PMID 23825533 DOI: 10.1371/journal.pone.0066243 |
0.577 |
|
| 2013 |
Allevi G, Strina C, Andreis D, Zanoni V, Bazzola L, Bonardi S, Foroni C, Milani M, Cappelletti MR, Gussago F, Aguggini S, Giardini R, Martinotti M, Fox SB, Harris AL, ... ... Generali D, et al. Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer. British Journal of Cancer. 108: 1587-92. PMID 23579222 DOI: 10.1038/bjc.2013.151 |
0.808 |
|
| 2013 |
Arpino G, Generali D, Sapino A, Del Matro L, Frassoldati A, de Laurentis M, Paolo P, Mustacchi G, Cazzaniga M, De Placido S, Conte P, Cappelletti M, Zanoni V, Antonelli A, Martinotti M, et al. Gene expression profiling in breast cancer: a clinical perspective. Breast (Edinburgh, Scotland). 22: 109-20. PMID 23462680 DOI: 10.1016/j.breast.2013.01.016 |
0.454 |
|
| 2013 |
Barni S, Vallini I, Bonotto M, Brunello A, Indelli M, Gori S, Saggia C, Petrella MC, Generali DG, Di Pietro Paolo M, Moretti A, Massari F, Fausti V, Pinotti G, Puglisi F, et al. Treatment effectiveness in advanced breast cancer patients in Italy: Ten years experience. Journal of Clinical Oncology. 31: e11573-e11573. DOI: 10.1200/JCO.2013.31.15_SUPPL.E11573 |
0.347 |
|
| 2013 |
Guarneri V, Frassoldati A, Generali DG, Bottini A, Cagossi K, Bisagni G, Boni C, Cavanna L, Piacentini F, Bettelli SR, Ficarra G, Maiorana A, Marini L, Conte PF. Preoperative letrozole plus lapatinib/placebo for HR+/HER2 negative operable breast cancer: Biomarker analyses of the randomized phase II LET-LOB study. Journal of Clinical Oncology. 31: 530-530. DOI: 10.1200/jco.2013.31.15_suppl.530 |
0.428 |
|
| 2013 |
La Verde N, Collovà E, Lonardi S, Generali D, Moretti A, Atzori F, Cazzaniga M, Saggia C, Tondulli L, Marcon I, Gentile AL, Rossello R, Martelli O, Aglione S, Farina G, et al. Male Breast Cancer: Clinical Features and Multimodal Treatment in a Retrospective Survey Analysis at Italian Centers Tumori Journal. 99: 596-600. DOI: 10.1177/030089161309900506 |
0.528 |
|
| 2013 |
Bidard F, Peeters D, Fehm T, Nole F, Gisbert-Criado R, Mavrudis D, Grisanti S, Generali D, Garcia-Saenz J, Stebbing J, Caldas C, Gazzaniga P, Manso L, Zamarchi R, Antelo M, et al. Abstract PD6-5: Pooled analysis of circulating tumor cells in metastatic breast cancer: Findings from 1944 individual patients data Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-Pd6-5 |
0.653 |
|
| 2013 |
Harris AL, Generali D. Inhibitors of Tumor Angiogenesis Cancer Drug Design and Discovery: Second Edition. 275-317. DOI: 10.1016/B978-0-12-396521-9.00010-3 |
0.341 |
|
| 2012 |
Nguyen B, Cusumano PG, Deck K, Kerlin D, Garcia AA, Barone JL, Rivera E, Yao K, de Snoo FA, van den Akker J, Stork-Sloots L, Generali D. Comparison of molecular subtyping with BluePrint, MammaPrint, and TargetPrint to local clinical subtyping in breast cancer patients. Annals of Surgical Oncology. 19: 3257-63. PMID 22965266 DOI: 10.1245/s10434-012-2561-6 |
0.475 |
|
| 2012 |
Martino M, Bottini A, Rosti G, Generali D, Secondino S, Barni S, Maisano R, Lanza F, Castagna L, Pedrazzoli P. Critical issues on high-dose chemotherapy with autologous hematopoietic progenitor cell transplantation in breast cancer patients. Expert Opinion On Biological Therapy. 12: 1505-15. PMID 22946512 DOI: 10.1517/14712598.2012.721767 |
0.404 |
|
| 2012 |
Guarneri V, Frassoldati A, Bottini A, Cagossi K, Bisagni G, Sarti S, Ravaioli A, Cavanna L, Giardina G, Musolino A, Untch M, Orlando L, Artioli F, Boni C, Generali DG, et al. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 1989-95. PMID 22493419 DOI: 10.1200/JCO.2011.39.0823 |
0.466 |
|
| 2012 |
Cavazzoni A, Bonelli MA, Fumarola C, La Monica S, Airoud K, Bertoni R, Alfieri RR, Galetti M, Tramonti S, Galvani E, Harris AL, Martin LA, Andreis D, Bottini A, Generali D, et al. Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. Cancer Letters. 323: 77-87. PMID 22484466 DOI: 10.1016/j.canlet.2012.03.034 |
0.625 |
|
| 2012 |
Berruti A, Generali D, Bertaglia V, Brizzi MP, Mele T, Dogliotti L, Bruzzi P, Bottini A. Intermediate endpoints of primary systemic therapy in breast cancer patients. Journal of the National Cancer Institute. Monographs. 2011: 142-6. PMID 22043062 DOI: 10.1093/jncimonographs/lgr036 |
0.422 |
|
| 2012 |
Damia G, Broggini M, Marsoni S, Venturini S, Generali D. New omics information for clinical trial utility in the primary setting. Journal of the National Cancer Institute. Monographs. 2011: 128-33. PMID 22043059 DOI: 10.1093/jncimonographs/lgr032 |
0.405 |
|
| 2012 |
Oakes SR, Vaillant F, Lim E, Lee L, Breslin K, Feleppa F, Deb S, Ritchie ME, Takano E, Ward T, Fox SB, Generali D, Smyth GK, Strasser A, Huang DC, et al. Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737. Proceedings of the National Academy of Sciences of the United States of America. 109: 2766-71. PMID 21768359 DOI: 10.1073/pnas.1104778108 |
0.641 |
|
| 2012 |
Andreis D, Generali DG, Foroni C, Bazzola L, Cappelletti M, Zanoni V, Milani M, Strina C, Allevi G, Aguggini S, Boni E, Giardini R, Bertoni R, Bottini A. Safety and activity of nonpegylated liposomal doxorubicin (nPLD) combined with oral metronomic cyclophosphamide (mC) as preoperative treatment for locally advanced breast cancer (BC) patients (pts). Journal of Clinical Oncology. 30: e11546-e11546. DOI: 10.1200/jco.2012.30.15_suppl.e11546 |
0.704 |
|
| 2012 |
Ganzinelli M, Ribeiro E, Bertoni R, Bazzola L, Andreis D, Bottini A, Giardini R, Rossi C, Damia G, Generali D. Expression of genes involved in DNA repair and cell cycle checkpoint pathways in Triple Negative compared to Luminal A Breast Cancer: a molecular characterization Hereditary Cancer in Clinical Practice. 10: A37. DOI: 10.1186/1897-4287-10-S2-A37 |
0.395 |
|
| 2012 |
Oakes S, Vaillant F, Lim E, Lee L, Breslin K, Feleppa F, Deb S, Ritchie M, Takano E, Ward T, Fox S, Generali D, Smyth G, Strasser A, Huang D, et al. Targeting BCL-2–expressing basal-like breast cancer with BH3-mimetics Hereditary Cancer in Clinical Practice. 10: 1-1. DOI: 10.1186/1897-4287-10-S2-A25 |
0.517 |
|
| 2012 |
Generali D, Nguyen B, Deck K, Kerlin D, Garcia A, Barone J, Rivera E, Yao K, Stork-Sloots L. 346 Comparison of Molecular Subtyping with BluePrint and MammaPrint to Local IHC/FISH Based Subtype Classification According to St Gallen 2011 in 133 Breast Cancer Patients European Journal of Cancer. 48: S143. DOI: 10.1016/S0959-8049(12)70412-4 |
0.48 |
|
| 2011 |
Guarneri V, Frassoldati A, Bottini A, Generali DG, Cagossi K, Artioli F, Bisagni G, Boni C, Ravaioli A, Amadori D, Musolino A, Cavanna L, Untch M, Orlando L, Giardina G, et al. Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 507. PMID 28021375 DOI: 10.1200/jco.2011.29.15_suppl.507 |
0.488 |
|
| 2011 |
Foroni C, Broggini M, Generali D, Damia G. Epithelial-mesenchymal transition and breast cancer: role, molecular mechanisms and clinical impact. Cancer Treatment Reviews. 38: 689-97. PMID 22118888 DOI: 10.1016/j.ctrv.2011.11.001 |
0.415 |
|
| 2011 |
Berruti A, Generali D, Kaufmann M, Puztai L, Curigliano G, Aglietta M, Gianni L, Miller WR, Untch M, Sotiriou C, Daidone M, Conte P, Kennedy D, Damia G, Petronini P, et al. International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). Journal of the National Cancer Institute. Monographs. 2011: 147-51. PMID 22043063 DOI: 10.1093/jncimonographs/lgr037 |
0.706 |
|
| 2011 |
Cochet A, Generali D, Fox SB, Ferrozzi F, Hicks RJ. Positron emission tomography and neoadjuvant therapy of breast cancer. Journal of the National Cancer Institute. Monographs. 2011: 111-5. PMID 22043055 DOI: 10.1093/jncimonographs/lgr035 |
0.553 |
|
| 2011 |
Generali D, Symmans WF, Berruti A, Fox SB. Predictive immunohistochemical biomarkers in the context of neoadjuvant therapy for breast cancer. Journal of the National Cancer Institute. Monographs. 2011: 99-102. PMID 22043052 DOI: 10.1093/jncimonographs/lgr030 |
0.579 |
|
| 2011 |
Generali D, Berruti A, Foroni C, Bazzola L, Andreis D, Allevi G, Bersiga A, Dogliotti L, Fox SB, Harris AL, Bottini A. Molecular oncology and the neoadjuvant setting: the perfect blend for treatment personalization and clinical trial design. Journal of the National Cancer Institute. Monographs. 2011: 67-70. PMID 22043044 DOI: 10.1093/jncimonographs/lgr029 |
0.631 |
|
| 2011 |
Robert NJ, Saleh MN, Paul D, Generali D, Gressot L, Copur MS, Brufsky AM, Minton SE, Giguere JK, Smith JW, Richards PD, Gernhardt D, Huang X, Liau KF, Kern KA, et al. Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial. Clinical Breast Cancer. 11: 82-92. PMID 21569994 DOI: 10.1016/j.clbc.2011.03.005 |
0.474 |
|
| 2011 |
Fox SB, Generali D, Berruti A, Brizzi MP, Campo L, Bonardi S, Bersiga A, Allevi G, Milani M, Aguggini S, Mele T, Dogliotti L, Bottini A, Harris AL. The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen. Breast Cancer Research : Bcr. 13: R16. PMID 21291529 DOI: 10.1186/bcr2825 |
0.814 |
|
| 2011 |
Andreis D, Scandurra G, Santini D, Gucciardino C, La Verde NM, Girelli S, Alabiso I, Saetta A, Atzori F, Collovà E, Ferzi A, Gori S, Lipari H, Saggia C, Marcon I, ... Generali DG, et al. First-line bevacizumab (B) plus paclitaxel (P) in HER2-negative (HER2-ve) metastatic breast cancer (mBC): Efficacy and safety in an Italian multicenter retrospective study. Journal of Clinical Oncology. 29: e11502-e11502. DOI: 10.1200/JCO.2011.29.15_SUPPL.E11502 |
0.467 |
|
| 2011 |
Conte PF, Guarneri V, Generali DG, Bottini A, Bazzola L, Piacentini F, Artioli F, Cagossi K, Bisagni G, Bagnalasta M, Tagliafico E, Barbieri E, Cavanna L, Ravaioli A, D'Amico R, et al. Double-blind, placebo-controlled, multicentric randomized phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal HER2-negative, hormone receptor-positive operable breast cancer. Journal of Clinical Oncology. 29: 550-550. DOI: 10.1200/jco.2011.29.15_suppl.550 |
0.436 |
|
| 2011 |
Cusumano G, Generali D, Lifrange E, Jerusalem G, Andreis D, Hilderink-Koertshuis R, Klaase J, Stork-Sloots L, Lutke Holzik M. P203 Inter-institutional comparison of impact of Mammaprint on the routine treatment decision-making process in early breast cancer patient populations from three European hospitals The Breast. 20: S45. DOI: 10.1016/S0960-9776(11)70144-8 |
0.383 |
|
| 2010 |
Margariti N, Fox SB, Bottini A, Generali D. "Overcoming breast cancer drug resistance with mTOR inhibitors". Could it be a myth or a real possibility in the short-term future? Breast Cancer Research and Treatment. 128: 599-606. PMID 20945086 DOI: 10.1007/s10549-010-0986-9 |
0.553 |
|
| 2010 |
Mele T, Generali D, Fox S, Brizzi MP, Bersiga A, Milani M, Allevi G, Bonardi S, Aguggini S, Volante M, Dogliotti L, Bottini A, Harris A, Berruti A. Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients. Breast Cancer Research and Treatment. 123: 795-804. PMID 20680681 DOI: 10.1007/s10549-010-1063-0 |
0.808 |
|
| 2010 |
Bonelli MA, Fumarola C, Alfieri RR, La Monica S, Cavazzoni A, Galetti M, Gatti R, Belletti S, Harris AL, Fox SB, Evans DB, Dowsett M, Martin LA, Bottini A, Generali D, et al. Synergistic activity of letrozole and sorafenib on breast cancer cells. Breast Cancer Research and Treatment. 124: 79-88. PMID 20054642 DOI: 10.1007/s10549-009-0714-5 |
0.646 |
|
| 2009 |
Milani M, Rzymski T, Mellor HR, Pike L, Bottini A, Generali D, Harris AL. The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib. Cancer Research. 69: 4415-23. PMID 19417138 DOI: 10.1158/0008-5472.CAN-08-2839 |
0.818 |
|
| 2009 |
Generali D, Bates G, Berruti A, Brizzi MP, Campo L, Bonardi S, Bersiga A, Allevi G, Milani M, Aguggini S, Dogliotti L, Banham AH, Harris AL, Bottini A, Fox SB. Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 1046-51. PMID 19188178 DOI: 10.1158/1078-0432.CCR-08-1507 |
0.822 |
|
| 2009 |
Generali D, Buffa FM, Berruti A, Brizzi MP, Campo L, Bonardi S, Bersiga A, Allevi G, Milani M, Aguggini S, Papotti M, Dogliotti L, Bottini A, Harris AL, Fox SB. Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 227-34. PMID 19064988 DOI: 10.1200/JCO.2007.13.7083 |
0.796 |
|
| 2008 |
Berruti A, Brizzi MP, Generali D, Ardine M, Dogliotti L, Bruzzi P, Bottini A. Presurgical systemic treatment of nonmetastatic breast cancer: facts and open questions. The Oncologist. 13: 1137-48. PMID 18997125 DOI: 10.1634/theoncologist.2008-0162 |
0.467 |
|
| 2008 |
Generali D, Dovio A, Tampellini M, Tucci M, Tedoldi S, Torta M, Bonardi S, Allevi G, Aguggini S, Milani M, Harris AL, Bottini A, Dogliotti L, Angeli A, Berruti A. Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases. British Journal of Cancer. 98: 1753-8. PMID 18506177 DOI: 10.1038/sj.bjc.6604390 |
0.712 |
|
| 2008 |
Generali D, Fox SB, Brizzi MP, Allevi G, Bonardi S, Aguggini S, Milani M, Bersiga A, Campo L, Dionisio R, Vergoni F, Giardini R, Dogliotti L, Bottini A, Harris AL, et al. Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 2673-80. PMID 18451231 DOI: 10.1158/1078-0432.CCR-07-1046 |
0.802 |
|
| 2008 |
Harris AL, Generali DG. Inhibitors of tumor angiogenesis Cancer Drug Design and Discovery. 351-381. DOI: 10.1016/B978-012369448-5.50018-5 |
0.442 |
|
| 2007 |
Fox SB, Generali DG, Harris AL. Breast tumour angiogenesis. Breast Cancer Research : Bcr. 9: 216. PMID 18190723 DOI: 10.1186/bcr1796 |
0.713 |
|
| 2007 |
Generali D, Fox SB, Berruti A, Moore JW, Brizzi MP, Patel N, Allevi G, Bonardi S, Aguggini S, Bersiga A, Campo L, Dogliotti L, Bottini A, Harris AL. Regulation of hepatocyte growth factor activator inhibitor 2 by hypoxia in breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 550-8. PMID 17255277 DOI: 10.1158/1078-0432.CCR-06-1266 |
0.811 |
|
| 2007 |
Generali D, Leek R, Fox SB, Moore JW, Taylor C, Chambers P, Harris AL. EGFR mutations in exons 18-21 in sporadic breast cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 18: 203-5. PMID 17220285 DOI: 10.1093/annonc/mdl322 |
0.768 |
|
| 2007 |
Generali D, Berruti A, Tampellini M, Dovio A, Tedoldi S, Bonardi S, Tucci M, Allevi G, Aguggini S, Milani M, Bottini A, Dogliotti L, Angeli A. The circadian rhythm of biochemical markers of bone resorption is normally synchronized in breast cancer patients with bone lytic metastases independently of tumor load. Bone. 40: 182-8. PMID 16935041 DOI: 10.1016/j.bone.2006.06.023 |
0.638 |
|
| 2007 |
Generali D, Berruti A, Brizzi MP, Campo L, Bonardi S, Wigfield S, Bersiga A, Allevi G, Milani M, Aguggini S, Gandolfi V, Dogliotti L, Bottini A, Harris AL, Fox SB. Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 4562-8. PMID 16899602 DOI: 10.1158/1078-0432.CCR-05-2690 |
0.828 |
|
| 2007 |
Generali DG, Berruti A, Fox SB, Brizzi M, Bonardi S, Milani M, Bersiga A, Dionisio R, Dogliotti L, Bottini A, Harris AL. Down-regulation of HIF-1α expression by letrozole in ER+ve breast cancer patients Journal of Clinical Oncology. 25: 510-510. DOI: 10.1200/JCO.2007.25.18_SUPPL.510 |
0.769 |
|
| 2006 |
Generali D, Fox SB, Berruti A, Brizzi MP, Campo L, Bonardi S, Wigfield SM, Bruzzi P, Bersiga A, Allevi G, Milani M, Aguggini S, Dogliotti L, Bottini A, Harris AL. Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer. Endocrine-Related Cancer. 13: 921-30. PMID 16954440 DOI: 10.1677/erc.1.01216 |
0.842 |
|
| 2006 |
Bottini A, Generali D, Brizzi MP, Fox SB, Bersiga A, Bonardi S, Allevi G, Aguggini S, Bodini G, Milani M, Dionisio R, Bernardi C, Montruccoli A, Bruzzi P, Harris AL, et al. Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 3623-8. PMID 16877730 DOI: 10.1200/JCO.2005.04.5773 |
0.815 |
|
| 2006 |
Ardine M, Generali D, Donadio M, Bonardi S, Scoletta M, Vandone AM, Mozzati M, Bertetto O, Bottini A, Dogliotti L, Berruti A. Could the long-term persistence of low serum calcium levels and high serum parathyroid hormone levels during bisphosphonate treatment predispose metastatic breast cancer patients to undergo osteonecrosis of the jaw? Annals of Oncology : Official Journal of the European Society For Medical Oncology. 17: 1336-7. PMID 16524968 DOI: 10.1093/ANNONC/MDL045 |
0.343 |
|
| 2006 |
Generali DG, Fox S, Buffa FM, Berruti A, Brizzi M, Allevi G, Bonardi S, Dogliotti L, Bottini A, Harris A. Principal factor analysis of predictive markers of response and resistance to primary chemo-endocrine treatment in elderly breast cancer (BC) patients Journal of Clinical Oncology. 24: 618-618. DOI: 10.1200/jco.2006.24.18_suppl.618 |
0.556 |
|
| 2005 |
Donadio M, Ardine M, Berruti A, Beano A, Bottini A, Mistrangelo M, Bonardi S, Castiglione F, Generali D, Polimeni MA, Bretti S, Alabiso O, Bertetto O. Weekly cisplatin plus capecitabine in metastatic breast cancer patients heavily pretreated with both anthracycline and taxanes. Oncology. 69: 408-13. PMID 16319512 DOI: 10.1159/000089995 |
0.536 |
|
| 2005 |
Berruti A, Generali D, Brizzi MP, Ardine M, Dogliotti L, Bottini A. Is pathologic complete response a valid surrogate parameter of treatment efficacy in HER2 positive breast cancer patients undergoing primary chemotherapy plus trastuzamab? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 8130-1; author reply. PMID 16258118 DOI: 10.1200/JCO.2005.03.3191 |
0.536 |
|
| 2005 |
Patel NS, Li JL, Generali D, Poulsom R, Cranston DW, Harris AL. Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function Cancer Research. 65: 8690-8697. PMID 16204037 DOI: 10.1158/0008-5472.CAN-05-1208 |
0.738 |
|
| 2005 |
Bottini A, Berruti A, Brizzi MP, Bersiga A, Generali D, Allevi G, Aguggini S, Bolsi G, Bonardi S, Tondelli B, Vana F, Tampellini M, Alquati P, Dogliotti L. Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a single-institution phase III trial. Endocrine-Related Cancer. 12: 383-92. PMID 15947110 DOI: 10.1677/ERC.1.00945 |
0.548 |
|
| 2005 |
Berruti A, Bitossi R, Gorzegno G, Bottini A, Generali D, Milani M, Katsaros D, Rigault de la Longrais IA, Bellino R, Donadio M, Ardine M, Bertetto O, Danese S, Sarobba MG, Farris A, et al. Paclitaxel, vinorelbine and 5-fluorouracil in breast cancer patients pretreated with adjuvant anthracyclines. British Journal of Cancer. 92: 634-8. PMID 15668714 DOI: 10.1038/sj.bjc.6602335 |
0.714 |
|
| 2005 |
Bottini A, Generali D, Berruti A, Brizzi MP, Allevi G, Bonardi S, Bersiga A, Aguggini S, Milani M, Dionisio R, Dogliotti L. Primary letrozole therapy versus the combination of letrozole plus oral cyclophosphamide in elderly breast cancer patients. A single Institution randomized phase II trial Journal of Clinical Oncology. 23: 8108-8108. DOI: 10.1200/jco.2005.23.16_suppl.8108 |
0.756 |
|
| 2005 |
Generali DG, Tedoldi S, Tampellini M, Berruti A, Torta M, Bonardi S, Bottini A, Tucci M, Milani M, Angeli A, Dogliotti L. Circadian rhythm of bone turnover markers in breast cancer patients with bone metastases and in control subjects Journal of Clinical Oncology. 23: 737-737. DOI: 10.1200/jco.2005.23.16_suppl.737 |
0.703 |
|
| 2004 |
Bodini M, Berruti A, Bottini A, Allevi G, Fiorentino C, Brizzi MP, Bersiga A, Generali D, Volpi D, Marini U, Aguggini S, Tampellini M, Alquati P, Olivetti L, Dogliotti L. Magnetic resonance imaging in comparison to clinical palpation in assessing the response of breast cancer to epirubicin primary chemotherapy. Breast Cancer Research and Treatment. 85: 211-8. PMID 15111758 DOI: 10.1023/B:BREA.0000025409.69516.23 |
0.387 |
|
| 2004 |
Bonardi S, Bottini A, Sperone P, Brizzi MP, Allevi G, Berruti A, Generali D, Aguggini S, Bernardi C, Dogliotti L. Chemotherapy followed by surgery of residual disease in metastatic breast cancer: A single institution prospective study Journal of Clinical Oncology. 22: 766-766. DOI: 10.1200/jco.2004.22.14_suppl.766 |
0.456 |
|
| 2003 |
Bottini A, Berruti A, Brizzi MP, Bersiga A, Generali D, Allevi G, Aguggini S, Bolsi G, Bonardi S, Bertoli G, Alquati P, Dogliotti L. Pretreatment haemoglobin levels significantly predict the tumour response to primary chemotherapy in human breast cancer. British Journal of Cancer. 89: 977-82. PMID 12966412 DOI: 10.1038/sj.bjc.6601216 |
0.496 |
|
| 2002 |
Bottini A, Berruti A, Bersiga A, Brizzi MP, Allevi G, Bolsi G, Aguggini S, Brunelli A, Betri E, Generali D, Scaratti L, Bertoli G, Alquati P, Dogliotti L. Changes in microvessel density as assessed by CD34 antibodies after primary chemotherapy in human breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 8: 1816-21. PMID 12060622 |
0.381 |
|
| 2001 |
Bottini A, Berruti A, Bersiga A, Brizzi MP, Bruzzi P, Aguggini S, Brunelli A, Bolsi G, Allevi G, Generali D, Betri E, Bertoli G, Alquati P, Dogliotti L. Relationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancer. British Journal of Cancer. 85: 1106-12. PMID 11710821 DOI: 10.1054/bjoc.2001.2048 |
0.435 |
|
| Show low-probability matches. |